MoneyWorks4Me

Smruthi Organics Ltd (540686)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 540686 NSE: Pharmaceuticals & Drugs | Small Cap | Smruthi Organics Share Price

₹162.20 1.55 (0.96%)

As on 23-Sep'26 11:41

Smruthi Organics Ltd (540686)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 540686 NSE: Pharmaceuticals & Drugs | Small Cap | Smruthi Organics Share Price

₹162.20 1.55 (0.96%)

As on 23-Sep'26 11:41

Key Metrics
Valuation Multiples
Market Cap
₹184 Cr.
Current Price
₹162.2
52-Week Low / High
₹95 / 175
TTM EPS
-
TTM Sales
-
Book Value per Share
-
P/E Ratio
Industry PE
54.8
Price to Book (P/B)
Price to Sales (P/S)
EV/EBITDA
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
%
Return on Capital Employed (ROCE)
%
Return on Assets (ROA)
%
Operating Profit Margin
0%
Net Profit Margin
-%
Gross Profit Margin
0%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
-19.08%
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
64.73%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
-
Equity
₹11.5 Cr.
Face Value
₹10
All Time Low / High
₹21.70 / 419.35

Smruthi Organics stock performance

Key Ratios
mw4me loader

Check Before You Invest

Valuation

Fair

Price Trend

Weak
Q.1 Is Smruthi Organics Ltd a good quality company?
Smruthi Organics Ltd is a weak quality company, based on a inconsistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

How does Smruthi Organics Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Smruthi Organics Ltd vs industry peers?
Smruthi Organics Ltd revenue CAGR is %, compared to the industry median CAGR of 0%, indicating stable growth and maintaining its market share.
Q.1 Promoter shareholding and pledge status of Smruthi Organics Ltd?
Promoters hold 64.73% of the Smruthi Organics Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Smruthi Organics Ltd over the last decade?
Over the last 5 year(s), the stock has delivered a CAGR of -12.53% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Smruthi Organics Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26TTM
ROCE % 10.6%-1%21.5%25%39.1%21%7.4%8.2%8%7.5%-
Value Creation
Index
-0.2-1.10.50.81.80.5-0.5-0.4-0.4-0.5-

Growth Parameters

Sales 79.497.3137131127133141128126102112
Sales YoY Gr.-22.7%41.2%-4.6%-3.5%5.4%5.8%-9.5%-1.3%-19.1%-
Adj EPS 1.4-2.865.314.99.23.73.33.13.46.5
YoY Gr.--303.6%NA-12.3%183.5%-38%-60.1%-11.9%-4.6%10.7%-
BVPS (₹) 28.225.431.837.152.958.759.660.862.664.266.8
Adj Net
Profit
1.6-3.26.9617.110.64.23.73.63.97
Cash Flow from Ops. 9.25.112.121.422.82.212.14.41022.3-
Debt/CF from Ops. 3.562.30.70.41.30.52.71.70.4-

CAGR

9 Years 5 Years 3 Years 1 Years
Sales 2.8%-4.2%-10.3%-19.1%
Adj EPS 10.7%-25.5%-2.4%10.7%
BVPS9.6%4%2.6%2.6%
Share Price - -12.4% -3.6% 18.7%

Key Financial Parameters

Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26TTM
Return on
Equity %
5-10.52115.333.116.66.25.455.410
Op. Profit
Mgn %
12.63.412.512.122.61479.59.71316.6
Net Profit
Mgn %
2-3.354.613.57.932.92.83.96.7
Debt to
Equity
11.10.80.40.200.10.20.20.1-
Working Cap
Days
25819415516313913215319720420975
Cash Conv.
Cycle
908066584881929911913440

Valuation of Smruthi Organics - Consolidated

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Financials

data not found
No data found!
data
No data found!
data
No data found!
data
No data found!

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Smruthi Organics Ltd FAQs

The current trading price of Smruthi Organics on 23-Sep-2026 11:41 is ₹162.2.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 22-Sep-2026 the market cap of Smruthi Organics stood at ₹183.9 Cr

The latest P/E ratio of Smruthi Organics as of 22-Sep-2026 is 24.64.

The latest P/B ratio of Smruthi Organics as of 22-Sep-2026 is 2.41.

The 52-week high of Smruthi Organics is ₹175.3 and the 52-week low is ₹95.00.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Smruthi Organics is ₹112 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Smruthi Organics Ltd is a below average quality company.

The key valuation ratios of Smruthi Organics Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Smruthi Organics Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Smruthi Organics Ltd

Smruthi Organics Ltd is a mid-size, public limited, API manufacturing company from Solapur, India. Smruthi Organics Ltd was established in1989 by qualified technocrats and has very good experience and reputation in the pharmaceutical industry for the supply of quality products. 

Their core competency is multi-step organic synthesis and large scale manufacturing of organic molecules. Their focus has always been API for the regulated markets. They have been part of successful contract manufacturing and custom synthesis agreements with leading European, American and Japanese customers. They are currently expanding our R&D to become a one-stop solution provider from concept to execution for all API including, but not restricted to, the following: 
  • Process Development
  • Process Optimization
  • Process Validation
  • Analytical Methods Validation
  • Regulatory Support and DMF Registrations
  • Commercial Manufacturing

Their constant endeavor to improve operations and systems has contributed to our growth. they encourage operational transparency with customers, which complements to confidence building for stronger relationships. Customer satisfaction is their highest priority and they constantly strive on optimizing delivery times of all their services.

Smruthi Organics Ltd facility is USFDA approved and European GMP certified for Carbidopa, Metformin HCL and Norfloxacin. It has successfully filed 4 European and US drug master files for different products.

Smruthi can manage a potential molecule's entire development life cycle up to commercialization through rigorous planning and proper execution. Smruthi can independently or in conjunction with the customer develop optimized synthesis process, perform scale-up and process validations, compile DMF and provide the customer with regulatory support for finished formulation dossier registration. The engagement can be either on an FTE or deliverables basis. We respect absolute confidentiality in such sensitive relationships enhancing smooth exchange of information.

Product range of the company includes:

API   
  • Amlodipine Base
  • Amlodipine Besilate
  • Carbidopa
  • Carvedilol
  • Chlorhexidine Base
  • Chlorhexidine Salts
  • Ciprofloxacin HCI
  • Clofibrate
  • Diloxanide Furoate
  • Enrofloxacin
  • Fenofibrate
  • Fluconazole
  • Iopomidol
  • Metformin HCI
  • Norfloxacin
  • Pefloxacin
  • S-Amlodipine
  • Nabumetone
Drug Intermediate
  • Nabumetone
  • Iopamidol / Iohexol
  • Montelukast
  • Iopamidol
  • Co-enzyme Q10
  • Atorvastatin
  • Carvedilol
  • Ciprofloxacin/Enrofloxacin
  • Perindopril
Achievements/ recognition:
  • The company’s quality systems and facilities are approved by USFDA, EU – GMP and ISO 9001:2000. 

You have 46 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now